{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:58:07Z","timestamp":1775473087711,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Recent studies have established the safety and efficacy of Superparamagnetic Iron Oxide (SPIO, Magtrace\u00ae) for delayed sentinel lymph node biopsy (SLNB) in patients with ductal carcinoma in situ (DCIS) who are undergoing mastectomy. The aim of our study was to measure cost containment with use of Magtrace\u00ae in comparison to upfront SLNB with traditional technetium-99 lymphatic tracer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 41 patients at our institution underwent mastectomy with Magtrace\u00ae injection for DCIS and were included in our single-institution, retrospective analysis. For comparison, total charges data were obtained for an upfront SLNB at the time of mastectomy. Cost comparison analysis was then performed against charges for intraoperative Magtrace\u00ae injection with additional charges incorporated for those patients who required return to the operating room for delayed SLNB. Total cost containment for the cohort with use of Magtrace\u00ae was then measured.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 41 patients who underwent Magtrace\u00ae injection, two patients required return to the operating room for a delayed SLNB for invasive disease. Including these charges for a second encounter into our cost analysis, the use of Magtrace\u00ae still yielded an overall cost containment of $205,793.55 in our cohort when comparing to patients who underwent upfront SLNB. For patients who underwent Magtrace\u00ae injection and did not require return to the operating room, charges were reduced by $6,768.52 per patient.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The use of Magtrace\u00ae for delayed SLNB in patients with DCIS undergoing mastectomy yielded a significant overall cost containment, further supporting its use in this patient population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-024-07451-2","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T04:08:36Z","timestamp":1722485316000},"page":"565-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost containment analysis of superparamagnetic iron oxide (SPIO) injection in patients with ductal carcinoma in situ"],"prefix":"10.1007","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9668-9222","authenticated-orcid":false,"given":"Odette","family":"Sol\u00eds","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamin","family":"Addae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raeshell","family":"Sweeting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Meszoely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rondi","family":"Kauffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"McCaffrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"issue":"6","key":"7451_CR1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jamcollsurg.2019.01.018","volume":"228","author":"TO Oseni","year":"2019","unstructured":"Oseni TO, Zhang B, Coopey SB, Gadd MA, Hughes KS, Chang DC (2019) Twenty-five year trends in the incidence of ductal carcinoma in situ in US women. J Am Coll Surg 228(6):932\u2013939","journal-title":"J Am Coll Surg"},{"issue":"1","key":"7451_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/bjs.11377","volume":"107","author":"F Munck","year":"2020","unstructured":"Munck F, Clausen EW, Balslev E, Kroman N, Tvedskov TF, Holm-Rasmussen EV (2020) Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ. J Br Surg 107(1):96\u2013102","journal-title":"J Br Surg"},{"issue":"3","key":"7451_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.6004\/jnccn.2018.0012","volume":"16","author":"WJ Gradishar","year":"2018","unstructured":"Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A et al (2018) Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16(3):310\u2013320","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"7451_CR4","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/archsurg.2010.243","volume":"145","author":"ED Kurniawan","year":"2010","unstructured":"Kurniawan ED, Rose A, Mou A, Buchanan M, Collins JP, Wong MH et al (2010) Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. Arch Surg 145(11):1098\u20131104","journal-title":"Arch Surg"},{"issue":"11","key":"7451_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamasurg.2017.2181","volume":"152","author":"C de Paz","year":"2017","unstructured":"de Paz C, Villanueva C, Bonev V, Senthil M et al (2017) Factors associated with underestimation of invasive cancer in patients with ductal carcinoma in situ: precautions for active surveillance. JAMA Surg 152(11):1007\u20131014. https:\/\/doi.org\/10.1001\/jamasurg.2017.2181","journal-title":"JAMA Surg"},{"issue":"9","key":"7451_CR6","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.5858\/arpa.2017-0268-OA","volume":"142","author":"MB Podoll","year":"2018","unstructured":"Podoll MB, Reisenbichler ES, Roland L, Bruner A, Mizuguchi S, Sanders MAG (2018) Feasibility of the less is more approach in treating low-risk ductal carcinoma in situ diagnosed on core nee- dle biopsy: ten-year review of ductal carcinoma in situ upgraded to invasion at surgery. Arch Pathol Lab Med 142(9):1120\u20131126. https:\/\/doi.org\/10.5858\/arpa.2017-0268-OA","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"7451_CR7","first-page":"1183","volume":"34","author":"JC Hogue","year":"2014","unstructured":"Hogue JC, Morais L, Provencher L et al (2014) Characteris- tics associated with upgrading to invasiveness after surgery of a dcis diagnosed using percutaneous biopsy. Anticancer Res 34(3):1183\u20131191","journal-title":"Anticancer Res"},{"key":"7451_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/00031348241244634","author":"G Muanamputu","year":"2024","unstructured":"Muanamputu G, Sparkman BK, Louie RJ, McGuire KP (2024) Clinical longevity of preoperative injection of superparamagnetic iron oxide nanoparticles for delayed sentinel lymph node biopsy. Am Surg. https:\/\/doi.org\/10.1177\/00031348241244634","journal-title":"Am Surg"},{"key":"7451_CR9","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1245\/s10434-022-13064-0","volume":"30","author":"A Karakatsanis","year":"2023","unstructured":"Karakatsanis A, Eriksson S, Pistiolis L et al (2023) Delayed sentinel lymph node dissection in patients with a preoperative diagnosis of ductal cancer in situ by preoperative injection with superparamagnetic iron oxide (SPIO) nanoparticles: the sentinot study. Ann Surg Oncol 30:4064\u20134072","journal-title":"Ann Surg Oncol"},{"key":"7451_CR10","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1200\/JCO.2008.16.3725","volume":"26","author":"SA McLaughlin","year":"2008","unstructured":"McLaughlin SA et al (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 26:5213\u20135219","journal-title":"J Clin Oncol"},{"key":"7451_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10549-023-07193-7","volume":"204","author":"JK Addae","year":"2024","unstructured":"Addae JK, Sweeting RS, Meszoely IM et al (2024) Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience. Breast Cancer Res Treat 204:117\u2013121","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07451-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07451-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07451-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T16:19:57Z","timestamp":1730218797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07451-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7451"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07451-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"16 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}